OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints By: Benzinga via Benzinga September 23, 2014 at 09:18 AM EDT Targeted Response Rate Achieved for Plasma Parathyroid Hormone Reduction Favorable Adverse Event Profile Consistent ... Read More >>